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Synopsis: The human microbiome is a new frontier in biology and one that is helping to define 14 
what it is to be human. Recently we have begun to understand that the “communication” 15 
between the host and its microbiome is via a metabolic super-highway.  By interrogating and 16 
understanding the molecules involved we may start to know who the main players are, how 17 
we can modulate them and mechanisms of health and disease. 18 
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Introduction 21 
Understanding mammalian biology has for the best part of 100 years been focused on trying 22 
to model how this system interacts with the environment. Since the discovery that DNA 23 
contains all the necessary information to recreate a new living organism and coupled with the 24 
revolution in gene sequencing, this focus turned to try to understand how host’s genome 25 
interacts with its environment to influence the balance between health and disease. A 26 
significant component of this body of work has been focused on the role of microbial 27 
pathogens in driving disease phenotypes. However, there is a dearth of information which 28 
considers that the microbes colonising the various niches of the human body may actually 29 
have co-evolved with the host and provide essential functions not found in the host’s genome. 30 
The role of mammalian microbiome is revealed, in extremis, when animals are reared in a 31 
sterile environment 1,2 and thus do not develop in the presence of a microbiota. The absence 32 
of the microbiome has been shown to influence a very wide and disparate range of 33 
physiological parameters, including cardiac size and output 3, response to anaesthesia 4 and 34 
many other features of the mature mammalian system 5.  While we can see a fundamental 35 
role for the microbiome in the development of a mature host we are left with a dearth of 36 
mechanisms by which this process is driven. 37 
Why do we need to know what metabolites are made? 38 
The history of microbiology has been predominantly focused on understanding the role that 39 
pathogens play in disease, and this goes back to the time of Robert Koch and Louis Pasteur.  40 
However, in the last 15 years there has been a slow, but inexorable move towards 41 
understanding how the commensal and mutualistic members of the human microbiome also 42 
contribute to host health and disease initiation.  In the last five years this interest in the 43 
microbiome has really expanded at an exponential rate. However, we cannot treat these 44 
organisms in a similar fashion to pathogenic microbes, since they have not evolved specific 45 
strategies to invade, colonise and reproduce in a hostile environment. Many of the functions 46 
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and features that they possess, and on which we rely, do not conform to the virulence model 47 
that we have used to describe and understand pathogens. Many of the functions are actually 48 
part of that everyday metabolism of these organisms and as such cannot be considered as 49 
virulence factors. For example, for many anaerobic bacteria which colonise the large intestine 50 
the ability to ferment simple molecules, to extract energy from them, results in a wide range of 51 
metabolites which are bioactive and interact with a wide range of receptors within the host. 52 
Thus the communication between this diverse set of organisms and its host is predominantly 53 
via a metabolite super-highway. Thus in order to understand this communication we need to 54 
be able to characterise the wide array of metabolites that the bacteria produce in response to 55 
the environment in which they find themselves and understand how the host responds to these 56 
metabolites based on the genes that they have. 57 
How do assess them and what can we assess – NMR and MS, what samples? 58 
Microbial metabolites are typically present in faeces, luminal contents and blood, particularly 59 
the hepatic portal vein blood, whilst host-microbial co-metabolites are present more commonly 60 
in circulating blood and urine. Metabolic profiling approaches are increasingly used to study 61 
metabolic function of the gut microbiota. The practical implementation of metabolic profiling 62 
includes five steps: (1) sample collection and preparation; (2) biochemical composition 63 
analyses; (3) data analysis and integration (e.g. statistically correlating metabolic and 64 
microbial data); (4) biomarker recovery and identification; and (5) validation and application.  65 
Urine and blood plasma or serum collection is straightforward, whereas obtaining faecal 66 
samples is more challenging and rarely done at outpatient clinics. Moreover, faecal samples 67 
are complex in nature since they contain microbial and mammalian cells and food residues, 68 
in which the biological and chemical processes continue during post-voiding and sample 69 
handling. Hence, storing samples at a lower temperature and immediate sample processing 70 
reduce the variation induced by sample handling. Standard operating procedures for biofluid 71 
collection and the effects of various handling conditions on the biochemical composition have 72 
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previously been reported 6-8. Analytical platforms, including nuclear magnetic resonance (NMR) 73 
spectroscopy and mass spectrometry (MS), are commonly used in metabolic profiling and can 74 
detect a wide range of microbial metabolites and host-microbial co-metabolites. NMR 75 
spectroscopy is a robust analytical platform with high reproducibility and it generates the most 76 
easily accessible and comprehensive information on metabolite structures. Although the 77 
sensitivity of NMR spectroscopy is less than mass spectrometry, it is non-destructive and 78 
requires minimum sample preparation. A single proton (1H) NMR experiment using a 600 MHz 79 
NMR spectrometer takes about 5-10 minutes and can detect a wide range of metabolites 80 
including amino acids, fatty acids, phenols, indole and other organic acids containing protons 81 
at low-micromolar levels. Therefore, it serves as the first choice for global profiling. Mass 82 
spectrometry provide complementary molecular information (e.g. molecular mass) and it is 83 
much more sensitive than NMR spectroscopy, but often requires pre-separation techniques 84 
such as liquid chromatography (LC) and gas chromatography (GC). Depending on the 85 
metabolites of the interest, different methods can be employed in liquid chromatography to 86 
focus on subsets of molecules. For example, reversed phase chromatography (RP-LC) is used 87 
to study non-polar compounds whereas hydrophilic interaction liquid chromatography (HILIC) 88 
is used for detecting polar compounds. Both RP-LC-MS and HILIC-MS are routinely used to 89 
analyse the same sample sets to achieve wider metabolite coverage. GC-MS is also a 90 
sensitive tool in metabolic profiling and commonly used to quantify short chain fatty acids. 91 
However, the drawback of GC-MS is that it requires derivatisation of the samples, a long 92 
sample preparation procedure, and only volatile compounds or compounds that are volatile 93 
after derivatisation can be detected. The main metabolic profiling platforms and their strengths 94 
and limitations have been summarised by Holmes et al. 2015 9. Detailed experimental 95 
protocols for global metabolic profiling 10-12 and bile acid profiling 13 have been published.  96 
All of these analytical tools generate signal-rich data, which requires multivariate statistical 97 
analyses to extract useful information from the datasets. Multivariate data analysis methods, 98 
typically including principal component analysis (PCA), orthogonal projections to latent 99 
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structures-discriminant analysis (O-PLS-DA) and random forest, provide easy visualisation of 100 
the metabolic similarities and differences between the samples or spectral data. O-PLS 101 
regression analysis is also used to statistically correlate metabolic data with other types of 102 
datasets, such as body weight, histological scores, bacterial counts generated from 16S rRNA 103 
gene based sequencing platform, cytokines, toxicity, see Fig 1 as an example.  Such 104 
correlation analysis between metabolic and microbial datasets allows further insight on 105 
metabolites that are likely to be associated with gut microbial composition. The statistical 106 
modelling results in a panel of spectral signals that are important for class discrimination (e.g. 107 
treatment group vs. control patients). Signal or feature identification can be challenging in 108 
global metabolic profiling. There are many publically available databases such as human 109 
metabolome database 14 and METLIN 15, software including Chenomx NMR Suite (Chenomx 110 
Inc.) and AMIX (Bruker) and published literature sources, which can assist in providing 111 
metabolite candidates for the selected features. Statistical total correlation spectroscopy 112 
(STOCSY) analysis is a statistical tool to calculate correlation between the peaks from the 113 
same molecules or the same biological pathways 16,17. Further analytical experiments should 114 
be carried out to confirm the metabolite identification. Various two-dimensional NMR 115 
spectroscopic experiments can be used to elucidate the connectivity of protons and carbons 116 
of the metabolites. Tandem MS/MS can be employed to obtain fragmentation patterns of the 117 
selected MS features to provide sub-molecular information for metabolite identification. In the 118 
case of targeted signals or metabolites at very low concentrations, solid phase extraction is 119 
often used to separate the signals of interest and concentrate it up for further 2D NMR 120 
experiments. In addition, metabolite candidates can be confirmed by spiking the standard 121 
compounds in the original biological samples and being tested by NMR spectroscopy or 122 
comparing the LC retention times and MS fragmentation patterns from the standards and the 123 
samples. Metabolite identification is a time consuming step and is considered to be a bottle 124 
neck in the metabolic profiling approach. These metabolite identification methods are often 125 
combined in order to elucidate the structure of the targeted spectral signals. Approximate 126 
numbers of metabolites seen in different biofluids can be in the range of thousands for both 127 
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urine 18 and serum19. Statistical validation can be carried out using methods such as N-fold 128 
cross validation and permutation testing, whereas biological validation remains challenging 129 
due to further requirement of knowledge of the target metabolic pathways, appropriate 130 
validation approaches and additional resources. Statistically and biologically validated output 131 
from metabolic profiling may eventually be applied to further mechanistic investigation, and 132 
clinical diagnosis and therapeutic decision making. 133 
Examples of using metabolic profiling to study gut microbial functionality  134 
The advancement of systems biology techniques, in particular metabolic profiling 135 
(metabolomics/metabonomics) and mathematical modelling approaches, has expanded the 136 
resolution at which we can study the metabolic contribution of the gut microbiota and their 137 
interaction with host biochemistry. A key strength of metabolic profiling is it’s holistic nature, 138 
simultaneously capturing vast amounts of metabolic information without bias, surpassing the 139 
need for a specific hypothesis allowing open questions to be asked. This property is ideal for 140 
studying the gut microbiota due to it’s mega-variate host-specific nature and our relatively 141 
limited understanding. Instead metabolic profiling is a hypothesis generating top-down 142 
approach that can illuminate linkages between the gut microbiota and host metabolic 143 
pathways for further evaluation.  144 
Coupling these data-rich techniques with gnotobiotic (aka germ-free or sterile) and antibiotic-145 
treated animal models has allowed these biochemical associations to be elucidated and their 146 
relevance to health and disease to be studied. Pair-wise comparisons of the plasma metabolic 147 
phenotypes between gnotobiotic and conventionalized mice using an LC-MS and GC-MS-148 
based approach highlighted the influential role of the gut microbiota on circulating amino acids 149 
and organic acids 20. Differences were observed in the plasma levels of bioactive indole-150 
containing metabolites derived from tryptophan such as indoxyl sulphate and indole-3-151 
propionic acid. The absence of these metabolites in the gnotobiotic animals, coupled with their 152 
greater abundance of tryptophan, indicates that this tryptophan metabolism is dependent upon 153 
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the gut microbiota. Certain bacteria possess tryptophanase activity (a deamination of the 154 
amino acid) and can break down dietary tryptophan to indole. This molecule can be absorbed 155 
from the gut and metabolized in the liver to indoxyl before being sulphated to indoxyl-sulphate. 156 
Indole can also be further processed by a different set of intestinal bacteria to the antioxidant 157 
indole-3-propionic acid. The plasma of gnotobiotic animals also contained greater amounts of 158 
the amino acid tyrosine while the conventional plasma contained greater amounts of the 159 
microbial-host co-metabolite 4-cresyl-sulphate. Intestinal bacteria have been shown to 160 
metabolize dietary tyrosine to 4-cresol, which upon absorption from the gut is sulphated in the 161 
liver to 4-cresyl sulphate (p-cresyl sulphate). These findings demonstrate the influence of the 162 
gut microbiota on the bioavailability of dietary amino acids, precursors for a range of essential 163 
bioactive metabolites. 164 
Similarly, a 1H NMR spectroscopy-based metabonomic approach was used to characterize 165 
the changes in the urinary metabolic profiles of gnotobiotic rats during 21 days of microbial 166 
colonization 21. Here, the acquisition of the gut microbiota was accompanied by marked 167 
changes in the urinary biochemical profile. Elevations were noted in the excretion of hippurate, 168 
phenylacetylglycine, and 3- and 4-hydroxyphenylpropionic acid (3-HPPA, 4-HPPA). These are 169 
microbial-host co-metabolites that result from the microbial metabolism of dietary components. 170 
Phenylacetylglycine arises from the bacterial metabolism of the amino acid phenylalanine to 171 
phenylacetate, which is conjugated with glycine in the rat liver to form phenylacetylglycine and 172 
with glutamine in the human liver to form phenylacetylglutamine. Hippurate is the glycine 173 
conjugate of benzoic acid, which can be derived from the bacterial metabolism of 174 
phenylalanine, chlorogenic acid and catechins. These molecules can be obtained from a range 175 
of polyphenolic compounds found in dietary components such as fruit, vegetables, tea and 176 
coffee 22. Interestingly, in a large-scale metabolic phenotyping study in humans from China, 177 
Japan, United Kingdom and the United States, hippurate excretion was found to be inversely 178 
associated with blood pressure, a major risk factor for cardiovascular disease 23. Formate, a 179 
product of gut microbial fibre fermentation, was also inversely associated with blood pressure. 180 
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Another metabonomic study characterized the systemic metabolic adaptation to gut 181 
colonization in gnotobiotic mice 24. Following 5 days of conventionalization, the metabolic 182 
strategy of the liver shifted from glycogenesis to lipogenesis. This observation was consistent 183 
with another study combining a transcriptomic and metabonomic approach to study metabolic 184 
response to colonization in the mouse jejunum. Here, two days of colonization resulted in the 185 
suppression of lipid catabolism (e.g. β-oxidation) in the jejunum and activation of anabolic 186 
pathways (e.g. lipogenesis, nucleotide synthesis and amino acid synthesis) 25. Such 187 
biochemical reorientations occurred in parallel to a rapid increase in body weight. These 188 
observations indicate the intimate biochemical relationship between the gut microbiota and 189 
host and how the host metabolic phenotype is shaped with the development of the gut 190 
microbiota. 191 
Antibiotic-treated animal models offer another tool for investigating microbial-host interactions. 192 
Gnotobiotic animals differ phenotypically from conventional animals raised in the presence of 193 
bacteria. Gnotobiotic animals have a reduced body weight, a lower metabolic rate, 194 
underdeveloped gut structure and absorptive capacity, and an immature immune system and 195 
as such can obscure the interpretation of results. Administering antibiotics to conventionally 196 
raised animals allows the influence of the gut microbiota on host biochemistry to be studied 197 
whilst preserving the conventional phenotype. This influence was demonstrated by 198 
administering the broad-spectrum antibiotics streptomycin and penicillin in the drinking water 199 
of rats for eight days 26 and in an early study vancomycin to mice 27. Swann and colleague 200 
used 1H NMR spectroscopy to compare the urinary and faecal metabolic profiles of control, 201 
antibiotic suppressed and a group undergoing recolonization (4 days of antibiotics followed by 202 
4 days of control treatment). In this study, antibiotic-induced suppression of the intestinal 203 
microbiota reduced the urinary excretion of hippurate, phenylpropionic acid, 204 
phenylacetylglycine, indoxyl-sulphate, trimethylamine-N-oxide (TMAO) and the short chain 205 
fatty acid (SCFA), acetate. The excretion of the amino acids taurine and glycine, and the TCA 206 
cycle intermediates, citrate, 2-oxoglutarate, and fumarate was increased following microbial 207 
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attenuation. In addition, all the SCFA (acetate, butyrate, propionate) were reduced in the 208 
faeces of the antibiotic-treated rats. SCFA arise from the bacterial fermentation of 209 
carbohydrates, including non-digestible polysaccharides. As these products provide a 210 
significant energy source for the host, this represents a key function of the gut microbiota 211 
salvaging energy from the diet. A human study by Claesson et al. 28 correlated faecal metabolic 212 
and microbial profiles to highlight a putative statistical association between butyrate and the 213 
presence of Ruminococcus or Butyricicoccus. Microbial and metabolic profiling of the 214 
recolonizing animals revealed a cage-dependent bacterial recolonization. This differnece was 215 
mirrored by cage-dependent differences in the metabolic signatures. This highlights the 216 
potential for environmental pressures to shape the gut bacterial re-establishment post-217 
antibiotic therapy with downstream implications on the metabolic state of the host. 218 
In addition to global profiling of low molecular weight metabolites, we can also target specific 219 
molecules or families of molecules, for example, bile acids and eicosanoids.  Targeted profiling 220 
of the bile acid signature enables a detailed overview of the enterohepatic circulation to be 221 
gained and the influence of the gut microbiota to be studied 13. The circulating and hepatic bile 222 
acid pool contains more than 30 known bile acids and the gut microbiota is responsible for 223 
driving the majority of this diversity 29. Primary bile acids (cholic acid and chenodeoxycholic 224 
acid) are synthesized in the liver from cholesterol and are conjugated with either taurine or 225 
glycine before secretion into the bile. Upon ingestion of a meal, bile acids stored in the gall 226 
bladder are expelled from the gall bladder into the small intestine and although the majority 227 
are actively absorbed in the small intestine a minor amount (1-5%; 200-800 mg daily in 228 
humans) reaches the colon. It is here that bile acids are modified by the resident microbiota. 229 
Many bacteria possess bile salt hydrolase (BSH) enzymes that deconjugate the bile acid from 230 
its amino acid. Once deconjugated further bacterial modifications can occur such as 231 
dehydroxylation giving rise to secondary bile acids such as deoxycholic acid and lithocholic 232 
acid. Modified bile acids can be absorbed and recycled to the liver where they are 233 
reconjugated and secreted into the bile. This absorption forms the enterohepatic circulation 234 
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whereby molecules are shuttled between the host liver and the microbiome. While bile acids 235 
have a key role in lipid digestion and absorption they are now also recognized as important 236 
signalling molecules serving as ligands for the nuclear receptor; farnesoid X receptor (FXR), 237 
and the plasma membrane bound G protein-coupled receptor, TGR5 30,31. Through binding to 238 
these receptors bile acids can regulate genes involved in lipid 32-34 and glucose metabolism 239 
35,36
 and energy homeostasis 37. Using a parallel transcriptomic and metabonomic approach 240 
the influence of the gut microbiota on the enterohepatic circulation and its signalling capacity 241 
was studied 38. An LC-MS based approach identified pronounced variation in the bile acid 242 
signatures of conventional and gnotobiotic rats with similar modulations induced by antibiotic 243 
treatment. The absence or attenuation of the gut microbiota shifted the bile acid signature to 244 
one dominated by taurine-conjugated bile acids and strikingly reduced the diversity of the bile 245 
acid pool. Such modulations impacted on the signalling function of the bile acid profile with 246 
significant alterations in the expression of genes and pathways regulated by bile acids. In 247 
addition to being measured in the blood and liver, bile acids were also measured in tissues 248 
outside of the enterohepatic circulation (kidney, heart) indicating a broader signalling role of 249 
these microbial-host co-metabolites. 250 
Metabolic profiling strategies applied to human studies have also expanded our understanding 251 
of the gut microbial contribution to host digestion and metabolism. This is well illustrated by 252 
the microbial metabolism of dietary choline to trimethylamine (TMA). Choline is predominantly 253 
derived from phosphatidylcholine found in animal sources in the diet. The microbial 254 
metabolism of choline involves the cleavage of the C-N bond to liberate TMA and 255 
acetaldehyde. While acetaldehyde undergoes further microbial metabolism to ethanol, TMA 256 
is absorbed from the gut and oxidized in the liver to form trimethylamine-N-oxide (TMAO) by 257 
the flavin-containing monooxygenase 3 (FMO3) enzyme. TMA can also be demethylated to 258 
dimethylamine both endogenously and by the gut microbiota (PMID: 4091797). Microbial 259 
processing of choline is well established 39 and TMA and TMAO have been previously 260 
observed in biofluids from gnotobiotic and antibiotic-treated rodents 21,26,40. However, recent 261 
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work in humans has linked this activity to increased cardiovascular disease (CVD) risk. In a 262 
global metabolic profiling study in humans, Wang et al. 41 found that three plasma metabolites 263 
were predictive of CVD, choline, its metabolite betaine, and TMAO. The role of these 264 
metabolites in CVD risk was investigated by feeding them individually to mice. Both choline 265 
and TMAO were found to promote atherosclerosis and all three metabolites up-regulated the 266 
expression of macrophage scavenger receptors known to contribute to the atherosclerotic 267 
process. The essential role of the gut microbiota in potentiating the bioactivity of choline 268 
through TMA production was confirmed using gnotobiotic mice. In a metabolic profiling study, 269 
microbial choline metabolism has also been shown to exacerbate non-alcoholic fatty liver 270 
disease (NAFLD), a condition caused by choline deficiency, in mice 42. 271 
The potential for the gut microbiota to influence host drug metabolism has been demonstrated 272 
in a human study characterising the metabolic fate of paracetamol/acetaminophen 43. The 273 
metabolic output of the gut microbiota, specifically 4-cresol, was found to influence the phase 274 
II detoxification of this widely used analgesic. 4-cresol has toxic properties and requires 275 
detoxification by the host. The primary route of this detoxification is sulfation (both in the 276 
gastrointestinal tract and in the liver) before excretion in the urine. This is also the preferred 277 
route of detoxification for acetaminophen and both molecules are sulphated by the same 278 
human cytosolic sulfotransferase, SULT1A1. As these two molecules compete for binding 279 
sites as well as for sulphate, the 4-cresol output of the gut microbiota can influence the ability 280 
of the host to sulphate acetaminophen. Alternative routes of detoxification including 281 
glucuronidation and phase I metabolism by the cytochrome P450 enzymes. Importantly, 282 
phase I metabolism results in the generation of the toxic intermediate, N-acetyl-p-283 
benzoquinone imine (NAPQI). In this study, individuals excreting high amounts of 4-cresol 284 
before receiving a standard dose of acetaminophen were found to excrete lower amounts of 285 
acetaminophen sulphate and higher amounts of acetaminophen-glucuronide. Such an 286 
observation is not limited to acetaminophen and many xenobiotics are detoxified via sulfation. 287 
Interestingly, using a molecular epidemiology approach we have also observed 4-cresyl 288 
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sulphate excretion to be positively correlated with age. This observation was found in both a 289 
US and Taiwanese populations suggesting that this age-associated change in the metabolic 290 
functionality of the gut microbiome is independent of diet and cultural influences. This data 291 
has particular relevance given the greater use of drug therapy with aging 44. The influence of 292 
the gut microbiota on idiosyncratic drug responses has also been demonstrated in a rodent 293 
study with the hepatotoxin, hydrazine 40. In this metabolic profiling study the protective effect 294 
of an established microbiome was demonstrated in rats with gnotobiotic animals showing a 295 
marked toxic response to a typically sub-toxic dose. These studies demonstrate the potential 296 
of using a global metabolic profiling approach to characterize the metabolic functionality of the 297 
gut microbiota to predict the efficacy and safety of orally administered xenobiotics. This 298 
represents a step towards a precision medicine approach tailoring pharmacological 299 
interventions to the metabolic status of the complete biological system including contributions 300 
from the host genome and the microbiome. 301 
Future directions 302 
To maximise the potential of metabonomic approaches and using them for defining the role 303 
which microbes play in maintaining health and driving disease we predict that the follow areas 304 
of research will need to be developed. 305 
 High throughput profiling of cellular responses to metabolites, currently we do not have 306 
platform which allow us to measure the responses of different cell types, e.g. colonocytes 307 
or hepatocytes to doses or combinations of metabolites.  308 
 A metabolic lexicon of bacteria – who makes what and from what substrate. The range of 309 
metabolites that different microbes make and from what, so we can predict how changes 310 
in the composition of the microbiota affects the metabonome is needed. 311 
 The interactions between bacteria and their combined impact on the host. Many studies 312 
look at single organisms, but we are far from understanding how the microbes interact 313 
with each other and how this  network affects the host via the metabolite axis. 314 
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 315 
Conclusions 316 
To understand how humans function now needs a systems based approach which 317 
incorporates the microbiome and its associated metabonome.  The metabolic super-highway 318 
is the key avenue along which microbes influence the host’s metabolism and physiology.  In 319 
order to understand humans we must start to understand and incorporate this knowledge into 320 
our model of the biology otherwise we will still be scrabbling around for explanations for 321 
disease for many years to come. 322 
323 
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Figure Legends 324 
Figure 1. O-PLS regression analyses of faecal water from a rat model of bariatric surgery 325 
against relative suspension growth values obtained from a 24-h treatment of L5178Y cells.  326 
Peaks pointing upward in the loadings plots represent metabolites which are positively 327 
correlated to the cell growth and vice versa. Red peaks reach a significance level of p < 0.005. 328 
Keys: GABA, gamma-aminobutyric acid; IS, indoxyl sulfate; PAG, phenylacetylglycine; p-329 
cresyl sulf, p-cresyl sulfate; p-cresyl glu, p-cresyl glucuronide. (Reproduced with permission 330 
from 45 and modified). 331 
 332 
 333 
334 
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